Background: Machado-Joseph Disease (MJD), a form of dominantly inherited ataxia belonging to the group of polyQ expansion neurodegenerative disorders, occurs when a threshold value for the number of glutamines in Ataxin-3 (Atx3) polyglutamine region is exceeded. As a result of its modular multidomain architecture, Atx3 is known to engage in multiple macromolecular interactions, which might be unbalanced when the polyQ tract is expanded, culminating in the aggregation and formation of intracellular inclusions, a unifying fingerprint of this group of neurodegenerative disorders. Since aggregation is specific to certain brain regions, localizationdependent posttranslational modifications that differentially affect Atx3 might also contribute for MJD. Methods: We combined in vitro and cellular approaches to address SUMOylation in the brain-predominant Atx3 isoform and assessed the impact of this posttranslational modification on Atx3 self-assembly and interaction with its native partner, p97. Results: We demonstrate that Atx3 is SUMOylated at K356 both in vitro and in cells, which contributes for decreased formation of amyloid fibrils and for increased affinity towards p97. Conclusions and general significance: These findings highlight the role of SUMOylation as a regulator of Atx3 function, with implications on Atx3 protein interaction network and self-assembly, with potential impact for further understanding the molecular mechanisms underlying MJD pathogenesis.
Introduction
Ataxin-3 (Atx3) is the protein responsible for Machado-Joseph Disease (MJD), a form of dominantly inherited ataxia belonging to the group of polyglutamine (polyQ) expansion neurodegenerative disorders. It displays a modular organization, which includes an N-terminal catalytic Josephin domain (JD) with deubiquitinase activity, two ubiquitin interacting motifs (UIMs), the expandable polyQ tract, and a C-terminal region that may include an additional UIM, depending on the splice isoform [1] . The physiological role of Atx3, which is located both in the cellular nucleus and cytoplasm [2] [3] [4] , is still not well understood, although it has been linked to ubiquitin-mediated pathways implicated in protein quality control and maintenance of protein homeostasis [5] [6] [7] , in transcriptional regulation [8] , in cytoskeleton regulation [9] , and in myogenesis [10] . Similar to what occurs in other polyQ-expansion disorders, self-assembly and aggregation of the polyQ-expanded Atx3 represent important hallmarks of MJD. Early in vitro studies showed that expansion of the Atx3 polyQ tract within the pathological range induced the formation of insoluble, β-rich fibrils capable of binding amyloid-specific dyes [11] . Later it was demonstrated that non-pathological Atx3 and the JD alone could form not only fibrillar aggregates under destabilizing conditions [12] [13] [14] but also soluble aggregates under native-like conditions [15] , revealing an important role for protein regions/domains outside the polyQ tract in Atx3 aggregation and indicating that the protein context can influence polyQ-mediated aggregation [15, 16] . As a result of its modular multidomain structure, Atx3 is known to engage in multiple macromolecular interactions and there is evidence that it associates with a wide range of functional multiprotein complexes, frequently in a polyQ-dependent manner [1, 17] . Pathogenesis in MJD, as well as in other polyQ-expansion diseases, is believed to result from an imbalance in the association of the polyQ-expanded protein with its molecular partners, leading to exposure of aggregation-prone regions and culminating in Atx3 self-assembly and functional alterations [18, 19] . Furthermore, cell-specific occurrence of Atx3 posttranslational modifications may alter Atx3 macromolecular interaction networks, intracellular protein dynamics, protein folding, stability, activity and, consequently its function [2, [20] [21] [22] , thereby contributing to neuroselective MJD pathogenesis.
To date, several posttranslational modifications have been associated with polyQ disease proteins, including ubiquitination, phosphorylation, acetylation, transglutamination, palmitoylation and SUMOylation [23] . Atx3 was shown to be a substrate for ubiquitination, a modification that was reported to enhance its proteolytic activity [24] . SUMOylation, the covalent attachment of small ubiquitin-like modifier (SUMO) protein, is also known to influence several aspects of a target protein, including activity, localization and stability [20] . SUMO attachment may promote or interfere with protein-protein interactions by masking existing binding sites, by creating new interfaces, or by inducing conformational changes [20] , with functional consequences depending on the substrate and cellular environment. This covalent modification has been demonstrated to occur for several polyQ-containing proteins, such as huntingtin [25] , ataxin-1 [26] , and ataxin-7 [27] . The causative protein of Huntington's disease (HD) is known to be SUMOylated or ubiquitinated at a single lysine residue. In a Drosophila model of HD, these two modifications show strikingly different phenotypes: ubiquitination of huntingtin decreases neurodegeneration, while modification by SUMO has the opposite effect [25] . Similarly, SUMOylation promotes the aggregation of polyQ-expanded ataxin-1, increasing its pathogenicity [28] . In contrast, SUMOylation appears to reduce the aggregation propensity of polyQ-expanded ataxin-7 and androgen receptor [27, 29] , underscoring the role of the substrate and of the cellular context in the effect of this posttranslational modification. Here we investigated the ability of Atx3 to be SUMOylated either in vitro or in cells and the functional impact of this posttranslational modification.
Materials and methods

Expression plasmids
Oligonucleotides used throughout the work are listed in Table S1 . The cDNAs for human Atx3 isoforms 3UIM (13Q), 2UIM (13Q) and 3UIM (77Q) were cloned into the pDEST17 Gateway vector (Life Technologies, Carlsbad, CA, USA) as previously described [15] . Plasmids for the expression of SUMO1, E1 (Uba2 and Aos1) and E2 (Ubc9) were kindly provided by Dr. Chongwoo A. Kim (University of Texas Health Sciences Center, USA) and for ScULP1 by Prof. M. Margarida Oliveira (GPlantS, ITQB-UNL, Portugal). Site-directed mutagenesis with the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) was used to produce the mature form of SUMO2 by introducing a stop codon downstream of Gly95, in an expression plasmid kindly provided by Prof. Keith Wilkinson (Emory University School of Medicine, USA). The same site-directed mutagenesis approach was used to introduce a cleavage site for recombinant tobacco etch virus (TEV) protease between the open reading frame and the N-terminal sequence coding for the 6xHis tag in all Atx3-encoding vectors [30] , and to introduce point mutations in putative-SUMOylation sites. Vector pQEp97ND1 encoding the N and D1 domains of p97 and the vector harboring the ubiquitin-6xHis gene fusion were kind gifts from Dr. Di Xia (National Cancer Institute, USA) and Prof. Patrick Loll (Drexel University College of Medicine, USA) [31] , respectively. Eukaryotic expression plasmid pEYFP-C1 encoding an N-terminal fusion of the yellow fluorescent protein (YFP) with human SUMO-1 was obtained from Dr. Mary Dasso (National Institute for Child Health and Human Development, USA) through Addgene (Cambridge, MA, USA, catalog no. 13380). The eukaryotic expression plasmid pcDNA3 encoding Ubc9, provided by Dr. Rainer Niedenthal (Medizinischen Hochschule Hannover, Germany) [32] , was used to generate a fusion construct with human 3UIM Atx3 at the C-terminal of Ubc9 (pcDNA-Ubc9-MCSatx3). The vector pIC111 was a kind gift from Dr. Iain Cheeseman (Whitehead Institute for Biomedical Research, USA) and was used to clone 3UIM Atx3 upstream GFP sequence, generating vector pIC111-GFP-3UIMAtx3.
Protein expression and purification
Escherichia coli BL21(DE3)-SI cells (Life Technologies, Carlsbad, CA, USA) were transformed with Atx3-encoding vectors and 6xHis-tagged proteins were expressed and purified as previously described [15] . Purified protein (in 20 mM sodium phosphate pH 7.5, 200 mM NaCl, 5% (vol/vol) glycerol, 2 mM EDTA, 1 mM DTT) was analyzed by SDS-PAGE and by analytical size exclusion chromatography (SEC) on a Superose 12 10/300 GL column (GE Healthcare, Little Chalfont, UK) and concentrated on centrifugal ultrafiltration devices (10 kDa cutoff; Merck Millipore, Darmstadt, Germany). Expression of Uba2, Aos1, Ubc9, ScULP1, and of mature forms of SUMO1 and SUMO2 was carried out in E. coli BL21(DE3) cells following similar procedures as for Atx3 variants, but using 0.4 mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) to induce expression. Ubc9, SUMO1, and ScUPL1 were purified by immobilized metal affinity chromatography (IMAC) on a HisTrap Chelating column (GE Healthcare, Little Chalfont, UK). Fractions eluted in buffer containing 250 mM imidazole were dialyzed against 10 mM Tris-HCl pH 7.5, 50 mM NaCl, and 20% (vol/vol) glycerol (Ubc9 and ScULP1) or 10% (vol/vol) glycerol and 1 mM DTT (SUMO1), and concentrated on centrifugal ultrafiltration devices (3 kDa cutoff; Merck Millipore, Darmstadt, Germany). E. coli protein extracts containing Uba2 and Aos1 were mixed and incubated for 1 h at 4°C to promote the formation of the E1 heterodimer (Uba2/Aos1). The E1 heterodimer was then purified in a 2-step process consisting of IMAC (HisTrap Chelating, as above) followed by SEC (Sephacryl S-200 HR, GE Healthcare, Little Chalfont, UK), with 20 mM Tris-HCl pH 7.5, 50 mM NaCl, and 20% (vol/vol) glycerol as the mobile phase, to separate individual free subunits from the heterodimer. The purest fractions were pooled and concentrated on centrifugal ultrafiltration devices (10 kDa cutoff; Merck Millipore, Darmstadt, Germany). Untagged mature SUMO2 protein was loaded onto an Econo-Pac High Q anion exchange cartridge (Bio-Rad, Hercules, CA, USA) equilibrated with 30 mM TrisHCl pH 7.5, 1 mM DTT, and 2.5 mM EDTA and eluted with a linear gradient of NaCl (0-350 mM) in the same buffer. Fractions containing SUMO2 were pooled and purified by SEC on a HiPrep 16/60 Sephacryl S-100 HR column (GE Healthcare, Little Chalfont, UK) equilibrated in 30 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 mM DTT, 2.5 mM EDTA, and 10% (vol/vol) glycerol. The purest fractions were pooled and concentrated on centrifugal ultrafiltration devices (3 kDa cutoff; Merck Millipore, Darmstadt, Germany). The protein fraction comprising the N and D1 domains of p97 were expressed and purified as previously described [33] .
Western blotting
Samples were separated on 12% or 15% (wt/vol) polyacrylamide SDS-PAGE gels and electrotransferred onto polyvinylidene fluoride membranes (Merck Millipore, Darmstadt, Germany), which were then blocked with TBS-Tween (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% (vol/vol) Tween-20) with 5% (wt/vol) non-fat dry milk. Primary antibodies were incubated with membranes for 1 h at room temperature or overnight at 4°C. The following primary antibodies were used: rabbit polyclonal anti-Atx3 that recognizes the JD domain peptide HKTDLERMLEAND and therefore detects both 3UIM (Uniprot P54252-2) and 2UIM (Uniprot P54252-1) Atx3 variants (1:2000; kindly provided by Dr. P. Maciel [34] ), 1H9 mouse monoclonal anti-Atx3 (1:10,000; MAB5360, Merck Millipore, Darmstadt, Germany), rabbit polyclonal anti-Ub (1:1000; Dako, Agilent Technologies, Santa Clara, CA, USA), mouse monoclonal anti-His (1:10,000; GenScript, Piscataway, NJ, USA), rabbit polyclonal anti-SUMO1 (1:1500; Boston Biochem, Cambridge, MA, USA) and anti-SUMO2/3 (1:2000; Boston Biochem, Cambridge, MA, USA), clone N86/38 mouse monoclonal anti-GFP (1:1000, NeuroMab, Davis, CA, USA) and mouse monoclonal anti-β-tubulin (1:400,000; Sigma-Aldrich, St. Louis, MO, USA). Secondary antibodies (alkaline phosphatase-conjugated goat polyclonal antirabbit (1:10,000; Sigma-Aldrich, St. Louis, MO, USA) and goat polyclonal anti-mouse (1:10,000; GenScript, Piscataway, NJ, USA) were incubated with membranes for 1 h and detection was performed with ECL Plus reagent (GE Healthcare, Little Chalfont, UK). All antibodies were diluted in TBS-Tween with 0.5% (wt/vol) non-fat dry milk. Atx3 was detected in cellular extracts with ECF (GE Healthcare, Little Chalfont, UK) and membranes were scanned with a Storm 860 Gel and Blot Imaging System (GE Healthcare, Little Chalfont, UK). Membranes were then stripped (0.2 M NaOH, 15 min) and reprobed with the anti-GFP antibody.
In vitro and in situ SUMOylation assays
In vitro SUMOylation assays were adapted from a published protocol [35] , using 2 μg purified Atx3, 0.4 μg SUMO1 or 0.5 μg SUMO2, 2 μg E1, 0.8 μg E2, 0.4 U creatine phosphokinase (Sigma-Aldrich, St. Louis, MO, USA), 10 mM creatine phosphate (Sigma-Aldrich, St. Louis, MO, USA) and 0.6 U inorganic pyrophosphatase (Sigma-Aldrich, St. Louis, MO, USA) in 50 mM Tris-HCl pH 7.6, 50 mM KCl, 5 mM MgCl 2 , and 1 mM DTT. The reaction was started with the addition of 2 mM ATP, allowed to proceed for 20-90 min at 37°C, and stopped with 5 μL 4× SDS-PAGE loading buffer. The samples were analyzed by Western blotting, using specific anti-SUMO1, anti-SUMO2, and polyclonal anti-Atx3 antibodies. For de-SUMOylation assays, SUMOylation assay samples were incubated with 1 mM DTT for 5 min at room temperature, before 1-5 μg ScULP1 was added and allowed to react for 30 min at 37°C. Reactions were stopped and analyzed as described for the SUMOylation assays. For large-scale production of SUMOylated Atx3, the assay was scaled 20-fold. The SUMOylated protein was applied to a MonoQ HR 5/5 column (GE Healthcare, Little Chalfont, UK) pre-equilibrated with 50 mM sodium phosphate buffer pH 7.5. Bound proteins were eluted with the same buffer containing 200 mM NaCl and concentrated by ultrafiltration as described above. Excess unmodified 3UIM Atx3 protein eluting earlier from the ion-exchange column was also collected, concentrated and used as a control to compare with the SUMOylated protein.
To test Atx3 SUMOylation in cells, COS-7 cells were grown in Dulbecco's modified eagle medium supplemented with 10% (vol/vol) fetal bovine serum and 1% (wt/vol) penicillin/streptomycin at 37°C in 5% (vol/vol) CO 2 . One day prior to transfection, fully confluent COS-7 cells were diluted 1:6 and seeded onto MW6 plates. Transient transfection was performed using Effectene (Qiagen, Venlo, The Netherlands), according to the manufacturer's indications (2 μg of DNA per well; 2 μg of each plasmid for co-transfection), followed by 24 h incubation. Culture medium was then removed and transfected cells were directly scraped in 60 μl of 1:1 RIPA buffer (25 mM TrisHCl pH 7.6, 150 mM NaCl, 1% (wt/vol) NP-40, 1% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) SDS) and 2 × SDS-PAGE loading buffer. Samples were then briefly sonicated, separated on a 10% (wt/vol) polyacrylamide SDS-PAGE gel, electroblotted and probed with monoclonal anti-Atx3 and anti-GFP antibodies.
Cortical neuron culture preparation and transfection
Cortical neuronal cultures were prepared as previously described [36] . Briefly, the cortices of Wistar rat embryos with 18 days were dissected, trypsinized and resuspended in a neuronal plating medium (minimum essential medium -MEM -supplemented with 10% (wt/vol) horse serum, 0.6% (wt/vol) glucose and 1 mM sodium pyruvate). Cells were passed through a 0.2 μm filter and then seeded onto 15 mm coverslipcontaining 12 well culture plates, at 2.5 × 10 5 cells/well. 2-4 h later the platting medium was substituted with Neurobasal medium supplemented with 2% SM1, 0.5 mM glutamine and 0.12 mg/ml gentamycin. Cells were kept in an incubator at 37°C, with a humidified atmosphere containing 5% CO 2 , up to 8 days in vitro (DIV). At 4 DIV cultures were transfected by a calcium phosphate transfection procedure adapted from a previously described protocol [37] , with 4 μg of plasmid pIC111-GFP-3UIMAtx3, with an additional 4 μg of plasmid pcDNA-Ubc9 in the case of co-transfection. Cells were incubated for 1.5 h, after which the transfection medium was substituted by the previously-reserved conditioned neuronal culture medium. Kynurenic acid (2 mM) was used throughout the transfection procedure in order to block ionotropic glutamate receptors. Expression was left to occur for 4 DIV under normal cell culture incubation conditions. For Western blot probing of endogenous Atx3, cortical neurons cultured at 9x10 5 cells/well in 6-well plates were stimulated at 9 DIV with 10 mM N-ethylmaleimide (NEM) for 30 min (or alternatively with the vehicle ethanol) and immediately processed and analyzed by Western blot as described for the in situ SUMOylation assays.
Atx3 activity assays
Protease activity assays were carried out at 30°C using 100-500 nM Atx3 and 200 nM Ub-AMC in 50 mM HEPES pH 7.5, 0.5 mM EDTA, and 1 mM DTT and monitored (380 nm excitation, 460 nm emission) for 5 min in a Fluoromax-4 spectrofluorometer (Horiba, Kyoto, Japan). For the release of ubiquitin from a ubiquitin-6xHis fusion protein [31] , Atx3 was incubated with ubiquitin-6xHis in 50 mM HEPES pH 7.5, 0.5 mM EDTA, and 1 mM DTT at 37°C. The reaction was stopped at different time points by the addition of SDS-PAGE loading buffer and the proteins separated by SDS-PAGE. To determine the percentage of ubiquitin release, SDS-PAGE gel bands were quantified by densitometry. Density of free ubiquitin and uncleaved ubiquitin-6xHis at each time point was normalized against the average of the density of either unmodified Atx3 or SUMOylated Atx3. Percentage of ubiquitin was calculated as [free ubiquitin / (uncleaved ubiquitin-6xHis + free ubiquitin) × 100].
Circular dichroism spectroscopy
CD measurements were performed on a Jasco-815 spectrometer (Jasco Inc, Easton, MA, USA) using 1 mm-path length quartz cuvettes. Proteins were diluted to 1.3 μM in 20 mM sodium phosphate pH 7.5, 20 mM NaCl, 0.5% (vol/vol) glycerol, 0.1 mM DTT and 0.1 mM EDTA. The secondary structure content was calculated by spectral decomposition with the CDSSTR method [38] .
Aggregation kinetics
Ataxin-3 amyloid formation kinetics was monitored by following the increase in thioflavin-T fluorescence as previously described [15, 39] . Briefly, fluorescence at 480 nm (440 nm excitation) was monitored at 37°C every 30 min over a period of 500 h for samples containing 30 μM thioflavin-T and 5 μM protein in 20 mM sodium phosphate pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% (vol/vol) glycerol, and 1 mM DTT in a FluoDia T70 (Photon Technology International, Edison, NJ, USA) microplate fluorimeter. To prevent evaporation, each reaction was overlaid with 20 μl paraffin oil. Data were analyzed using Prism 5 (GraphPad Software).
For visualization of protein fibers/aggregates by TEM protein samples were diluted in water and adsorbed onto glow-discharged, carbon-coated films supported on 200-mesh copper grids and negatively stained with 2% (wt/vol) uranyl acetate. Grids were visualized using a JEM-1400 (JEOL, Tokyo, Japan) TEM at an accelerating voltage of 80 kV.
Quantification of aggregate-containing neurons
Transfected cortical neurons with 8 DIV were fixed with 4% (wt/vol) paraformaldehyde and 4% (wt/vol) sucrose in PBS, for 15 min at RT. Counting of Atx3-GFP aggregate-containing neurons was performed blindly to condition by manually scanning coverlips and observing the GFP fluorescence with a Zeiss Axiovert 200 M microscope (Carl Zeiss AG, Oberkochen, Germany) using a 63 × oil objective (PlanApochromat, 1.4 numeric amplitude). Aggregation was expressed as the fraction of cells containing aggregates.
Differential scanning fluorimetry
The thermal stability of Atx3 samples (20 μM) was assessed by following SYPRO Orange (Agilent Technologies, Santa Clara, CA, USA) fluorescence using a cy3 filter on an iCycler iQ Real Time PCR Detection System (Bio-Rad) as a function of temperature (35 to 85°C in 0.5°C increments). The melting curves were analyzed using CFX Manager (Bio-Rad, Hercules, CA, USA).
Surface plasmon resonance
SPR experiments were performed at 25°C using a BIACORE 3000 (GE Healthcare, Little Chalfont, UK) equipped with a research-grade CM5 sensor chip. Atx3, either SUMOylated (3UIM Atx3 S1, 56 kDa) or unmodified 3UIM Atx3 (44 kDa) was used as ligand and immobilized using amine-coupling chemistry. The surfaces of all four flow cells were activated for 7 min with a 1:1 mixture of 0.1 M NHS (N-hydroxysuccinimide) and 0.1 M EDC (3-(N,N-dimethylamino) propyl-N-ethylcarbodiimide) at a flow rate of 5 μl/min. The ligands (10 μg/ml in 10 mM sodium acetate pH 4.5) were immobilized at a density of 1500 RU. Bovine serum albumin (BSA) was immobilized on flow cell 1, serving as the reference surface. All surfaces were blocked with a 7 minute injection of 1 M ethanolamine pH 8.5. To collect kinetic binding data, p97 ND1 (hexameric, 318 kDa) was diluted in 10 mM HEPES pH 7.4, 150 mM NaCl, and 0.005% (vol/ vol) P20 and injected over the four flow cells at concentrations of 0.125, 0.25, 0.5, 2, 4, 8, 16 and 32 nM at a flow rate of 30 μl/min. The complex was allowed to associate and dissociate for 180 and 300 s, respectively. The surfaces were regenerated with a 40 μl injection of 1 M ethanolamine pH 8.5 at 5 μl/min. Data were fit to a simple 1:1 interaction model using the global data analysis option available within BIAevaluation software (GE Healthcare, Little Chalfont, UK).
Statistical analysis
The arithmetic means are given with standard deviation with 95% confidence value. Statistical analyses were carried out using independent samples t-test analysis. A P value less than 0.05 was considered to denote a significant difference.
Results
Atx3 is SUMOylated in vitro and in mammalian cells
To determine the susceptibility of Atx3 to SUMO attachment, an in vitro SUMOylation assay was established using recombinant 3UIM Atx3 (Atx3 variant 2 containing 3 UIM motifs, UniProt accession code P54252-2), E1 and E2 enzymes, SUMO1 or SUMO2, and ATP. This assay yielded a higher molecular weight band that could be detected with an anti-Atx3 antibody, displaying a time-dependent increase in intensity (Fig. 1A) .
This Atx3-containing band, observed when either SUMO1 or SUMO2 was added to the reaction, was also reactive to an anti-SUMO antibody (Fig. S1) , had a molecular weight compatible with the covalent attachment of SUMO to Atx3 and disappeared upon incubation with the deSUMOylase ULP1 (Fig. 1B) . Since there are different splice variants of Atx3 with different properties and displaying distinct C-termini (Fig. 1C) [40] , the SUMOylation of the 2UIM Atx3 variant (Atx3 variant 1 containing only 2 UIM motifs, UniProt accession code P54252-1) was also investigated. Contrary to what was observed for the 3UIM Atx3 isoform, no in vitro SUMOylation was detected when using 2UIM Atx3 (Fig. 1D) . These results suggested that SUMOylation is specific to 3UIM Atx3, with SUMO attachment occurring at the variable C-terminal portion of Atx3, downstream from the polyQ tract. Atx3 SUMOylation was also evaluated in a cellular system. COS-7 cells were co-transfected with a plasmid encoding the SUMO-conjugating enzyme Ubc9 fused to the N-terminus of 3UIM Atx3 and a plasmid encoding YFP-SUMO1, a widely used strategy for increasing the SUMOylation levels of specific targets [32, 41, 42] . The cell lysates were probed for Atx3, revealing three high-molecular weight bands when Ubc9-3UIM Atx3 was co-expressed with YFP-SUMO1 (Fig. 1E) , showing that 3UIM Atx3 was also SUMOylated in cells, and indicating that SUMO attachment might occur in at least three sites, as SUMO1 does not have the ability to form polymeric chains [43] . Importantly, a high molecular weight band compatible with SUMOylation of Atx3 in more than one site is also observed in the in vitro reaction (Fig. 1A) . Furthermore, in non-transfected cortical neuron extracts obtained after stimulation with the deSUMOylase inhibitor N-ethylmaleimide (NEM), the appearance of a protein band recognized by the anti-Atx3 antibody can be observed, consistent with the presence of endogenous Atx3 conjugated to SUMO (Fig. S2) . Unsurprisingly, this band is extremely faint, in agreement with the expected low fraction of Atx3 conjugated to SUMO.
3UIM Atx3 is modified by SUMO at K356
The unique C-terminal portion of 3UIM Atx3 contains three lysine residues (K356, K360 and K361), which could be potentially modified by SUMOylation. To further narrow the search for the SUMOylation site(s), a truncated form of 3UIM Atx3 (1-352, Fig. 1C ) was tested and shown not to be SUMOylated in vitro ( Fig. 2A) , indicating that SUMO attachment occurs in at least one of those three C-terminal lysine residues. Using a single point mutant (K356R) and a double mutant (K360R/K361R) it was shown that K356 is the major site for SUMOylation for both SUMO1 and SUMO2 proteins and that in vitro SUMOylation at K356 is independent of the presence of either K360 or K361 (Fig. 2A) . The occurrence of specific SUMO attachment at 3UIM Atx3 K356 was also tested in COS-7 cells using Ubc9-3UIM Atx3 chimera, a strategy that already proved to be useful in assessing SUMOylation of protein candidates such as FOS, CRSP9, CDC37, CSNK2B, TAF10, HSF2BP, PSMC3 and DRG1 [41] . In accordance with the in vitro results, 3UIM Atx3 was found to be SUMOylated at K356 in COS-7 cells (Fig. 2B) . In order to understand the relevance of polyQ expansion in the SUMOylation process of Atx3, the same experimental methodologies were applied to 3UIM Atx3 (77Q), revealing that this protein is also SUMOylated at K356 in a cellular environment (Fig. 2C) as well as in vitro using strictly monomeric proteins ( Fig. 2D and E) .
Of note, we found that K166, a previously described Atx3 SUMOylation site identified in Atx3 expressed in HEK293 cells [45] , is not the main SUMOylation site neither in vitro nor in COS-7 cells, since the K166R mutation, contrary to what was observed in the K356R mutant, did not impair SUMOylation using our assay (Fig. 2B  and C) . This is in good agreement with the observation that JD alone (Fig. S3 ) and 2UIM Atx3 (Fig. 1D) , both lacking K356 but containing K166, are not SUMOylated. Taken together, these results unambiguously demonstrate that the brain-predominant Atx3 isoform is preferentially SUMOylated within the C-terminal tail K356 both in vitro and in cells.
Structural impact of SUMOylation on Atx3 thermal stability, proteolytic activity and fibril formation
In order to assess the functional and structural impact of Atx3 modification by SUMO, the enzymatic SUMOylation assay was successfully scaled up and a protocol for purifying the conjugated protein was developed. The SUMOylated material from a large-scale assay (~10 mg of freshly purified Atx3 protein) was separated from unmodified Atx3 by anion-exchange chromatography (Fig. 3A) and the unmodified Atx3 (uAtx3) was used as control in subsequent experiments, as it was exposed to the same treatment as the SUMO-conjugated protein. SUMOylated Atx3 (Atx3:S1) could be efficiently purified using this experimental approach (Fig. 3B and C) . The melting temperatures of unmodified Atx3 (13Q), expanded Atx3 (77Q) and Atx3:S1 were determined by differential scanning fluorimetry. As previously shown [46] , polyQ expansion did not modify the overall thermal stability of monomeric Atx3 and, surprisingly, no significant changes were observed upon SUMOylation (Table 1) .
Indeed, circular dichroism (CD) measurements revealed that SUMO attachment had no major influence on the overall secondary structure content of Atx3, since the CD spectrum of SUMOylated Atx3 superimposes with the spectrum of an equimolar mixture of unmodified Atx3 and SUMO1 and with the spectrum resulting from adding together the independently obtained spectra of unmodified Atx3 and SUMO1 (Fig. 3D) . Additionally, the proteolytic activity of SUMOylated Atx3 was assessed by determining its ability to release ubiquitin from an ubiquitin-6xHis fusion. SUMOylation does not significantly influence the proteolytic activity of Atx3 in this assay (Fig. 3E ), in line with the results obtained from activity assays using a fluorogenic substrate (ubiquitin-AMC; Fig. S4 ). Altogether these results indicate that SUMOylation does not influence the overall secondary structure of Atx3 nor its thermal stability or proteolytic activity.
The impact of SUMOylation on the aggregation behavior of Atx3 was also assessed by monitoring thioflavin-T binding, an assay that reports the first JD-dependent step of Atx3 assembly into amyloid-like structures [39, 47] . Even though SEC analysis revealed no differences between the initial oligomerization statuses of SUMOylated or unmodified Atx3 (Fig. 4A) , with both proteins behaving as monomeric species, there is a divergent aggregation profile of SUMOylated Atx3 when compared to the unmodified protein, with SUMO attachment being sufficient to reduce the total number of Thioflavin-T positive Atx3 protofibrils (Fig. 4B) . Complementary aggregation monitoring by TEM revealed no differences in fiber morphology between SUMOylated and unmodified Atx3, or an obvious decrease in pre-fibrillar structures in the modified Atx3 sample at the beginning of the assay that could justify the differences in the aggregation profile (Fig. 4C) . This indicates that SUMOylation has an impact on Atx3 self-assembly. To evaluate the impact of SUMOylation in the aggregation of Atx3 in neuronal cells, Ubc9 was overexpressed in cultured cortical neurons and the aggregation of 5 μg) or absence of the SUMO-specific protease ULP1. The band corresponding to SUMOylated Atx3 could not be detected when the reaction was carried out in the presence of ULP1, suggesting that the modification is specific. For negative controls, either ATP or Atx3 was omitted. (C) Schematic representation of the splice isoforms of Atx3, 2UIM Atx3 and 3UIM Atx3, and of a C-terminal truncated form of 3UIM Atx3 used in this work. (D) Western blot analysis of the in vitro SUMOylation reaction products of purified 2UIM Atx3, performed as described in (A). No SUMOylated Atx3-compatible bands were observed using an anti-Atx3 antibody. (E) Western blot analysis of cellular extracts from COS-7 cells expressing the fusion protein Ubc9-3UIM Atx3, YFP-SUMO1 or co-expressing Ubc9-3UIM Atx3 with YFP-SUMO1. Atx3 SUMOylation bands (~100 kDa,~140 kDa and~180 kDa) could be detected when Ubc9-3UIM Atx3 (~62 kDa) was co-expressed with YFP-SUMO1 (37 kDa). The experiment was performed in 4 independent preparations. GFP-Atx3 assessed by microscopy (Fig. S5 ). These results demonstrate that stimulation of SUMOylation leads to a reduction in the percentage of cells displaying Atx3 aggregates (Fig. 4D) .
SUMOylation modulates the affinity of Atx3 for the ATPase p97
Numerous cellular processes are known to be regulated by protein SUMOylation, with SUMO modifying the interaction surface of the target protein, blocking existing interactions and/or promoting new ones [20] . One of the well-characterized Atx3-interacting partners is the AAA + ATPase p97 (a.k.a. valosin-containing protein -VCP), that binds to the Lys/Arg-rich binding motif preceding the polyQ tract of Atx3 through the region encompassing the N and D1 domains [48] . Surface plasmon resonance (SPR) analysis of the interaction between full length unmodified Atx3 and p97 (the region comprising the N and D1 domains, p97 ND1) revealed that both proteins interact with an affinity in the low nanomolar range (1.2 nM, Fig. 5A , Table 2 ). The binding data could be fitted to a 1:1 stoichiometric model, consistent with the (Atx3 1-352 ), 3UIM Atx3 K356R mutant and 3UIM Atx3 K360R/K361R double mutant. Proteins were incubated with SUMO1 or SUMO2, as described in Fig. 1A . Only the C-terminal K356R mutation abolished SUMOylation indicating that 3UIM Atx3 is modified at K356 by both SUMO1 and SUMO2. (B) Fusions of Ubc9 and 3UIM Atx3 or its K356R, K166R, or K166R/K356R mutants were co-expressed with YFP-SUMO1 in COS-7 cells and cellular protein extracts were separated by SDS-PAGE and probed with antiAtx3 or anti-YFP antibodies. Single mutation of K166 to arginine was not enough to hinder 3UIM Atx3 SUMOylation in COS-7 cells, as opposed to both the K356R mutant and the K166R/K356R double mutant. SUMOylation of 3UIM Atx3 K356R was assessed in three independent experiments. (C) Fusions between Ubc9 and 3UIM Atx3 (77Q) or its K356R, K166R, or K166R/K356R mutants were co-expressed with YFP-SUMO1 in COS-7 cells and analyzed as in panel B. Mutations K356R and K166R/K356R abolished the appearance of a band corresponding to SUMOylated Atx3. (D) PolyQ-expanded (77Q) and non-expanded (13Q) 3UIM Atx3 isoforms (black and blue, respectively) are monomeric. Both Atx3 isoforms elute as monomers, on analytical SEC, as previously described [15, 44] . (E) Western blot analysis of the in vitro SUMOylation reaction products of 3UIM Atx3 (77Q) and its K356R mutant showed that the polyQ-expanded Atx3 is modified by SUMO1 and SUMO2 and that the K356R mutation abolished this modification.
binding of one Atx3 molecule to the p97 ND1 hexamer, and in good agreement with the stoichiometries determined for other deubiquitinases with affinity for the p97 N-domain [49] .
Quantification by SPR of the impact of Atx3 SUMOylation on its interaction with p97 ND1 (Fig. 5B) revealed that the two proteins interact strongly (kD within the nM range, Table 2 ) and that the covalent attachment of SUMO to Atx3 results in a twofold increase in association rate (ka of 1.05 × 10 6 1/Ms vs 5.93 × 10 5 1/Ms, Table 2 ) and affinity for p97 ND1 (kD of 0.66 nM vs 1.23 nM, Table 2 ). Moreover, the complex formed with SUMOylated Atx3 is somewhat more stable than that of the unmodified Atx3 (kd of 6.85 × 10 − 4 1/s versus 7.28 × 10 − 4 1/s, Table 2 ). Interestingly, SUMO conjugation did not modify the interaction of Atx3 with CHIP, a protein known to interact with the Cterminal tail of Atx3 [50, 51] (Fig. S6) , further highlighting the specific effect of Atx3 SUMOylation on the interaction with p97. Altogether, these results indicate that Atx3 interacts with p97 ND1 with nanomolar affinity and SUMOylation at K356 positively modulates complex formation.
Discussion
Recent evidence supports the idea that MJD results from a combination of multiple events triggered by the expansion of Atx3 polyQ tract [1, 17, 52] , which culminate in the formation of toxic oligomers and ultimately in neuronal death. Due to the ability of Atx3 to associate with a wide range of functional multiprotein complexes, and since regions/ domains outside the polyQ tract greatly influence Atx3 aggregation behavior [14, 15, 30, 39, 53, 54] , it is hypothesized that self-assembly of polyQ-expanded Atx3 can result from an imbalance in the association with the native molecular partners, whose interactions might be further modulated by posttranslational modifications [17, 18] . Here it is shown that both non-pathogenic and expanded Atx3 are SUMOylated at K356 and that only the 3UIM Atx3 splice isoform, which is predominant in the brain [40] , but not the 2UIM Atx3 isoform, is SUMOylated, suggesting that this posttranslational modification might have a role in the control of Atx3 neuronal functions, therefore impacting MJD.
It is known that Atx3 has an intrinsic propensity to self-assemble through a multistep pathway, with the JD playing a preponderant role in the first oligomerization step, common to both normal and diseaserelated Atx3 [1, 15] , and the polyQ-expanded region mediating the formation of stable SDS-insoluble fibrils [39, 55] . We demonstrate that covalent attachment of SUMO to the C-terminal K356 of Atx3 is able to decrease its intrinsic propensity for self-assembly, influencing the JD-dependent aggregation step, and likely having an impact on MJD. One possible explanation is that SUMOylation induces subtle alterations in the JD surface implicated in Atx3 self-assembly [53] , which is sufficient to reduce the overall amount of fibrils formed. Overexpression of Ubc9 in cultured neurons decreases the fraction of cells displaying Atx3 aggregation, suggesting that stimulating SUMOylation leads to a decreased aggregation of Atx3 in a biologic context. Further studies will elucidate if the effect is due to increased SUMO conjugation to Atx3.
SUMOylation is known to modulate the functional properties of a target protein, particularly by changing the overall macromolecular interaction surface and consequently the affinity for native molecular partners [56] . Atx3 molecular functions relying on interactions targeting Atx3 C-terminal region [17] are therefore expected to be affected by this posttranslational modification. Our data demonstrate that SUMOylation does not significantly modulate Atx3 ubiquitin hydrolase activity, in contrast to what was shown for Atx3 monoubiquitination within the JD [24] . However, it has an impact on the interaction of Atx3 with p97, an AAA+ hexameric ring-shaped ATPase involved in several essential biological processes, such as post-mitotic homotypic membrane fusion of the endoplasmic reticulum (ER) and Golgi apparatus [57] and the degradation of soluble and membrane proteins by the ubiquitinproteasome system [58, 59] . p97 coordinates multiple cellular pathways, depending on its interaction partners [60] , whose association can be modulated by an array of posttranslational modifications [61] . Moreover, p97 is found in ubiquitinated protein inclusions in a number of neurodegenerative disease states, including those resulting from polyQ expansions [62] . Despite its presence in multiple polyQ-protein inclusions, p97 does not interact with the polyQ-tract itself, but it was shown to specifically bind to Atx3 [48] , although no quantitative data on the interaction of p97 with full-length Atx3 had been previously determined. We demonstrate that unmodified Atx3 binds to p97 with high affinity, in the low nanomolar range. p97 is thus the tightest Atx3 interaction partner identified so far, and one of the few proteins targeting solely the Atx3 C-terminal tail in the proximity of the disease-related polyQ expansion site [17] . Interestingly, SUMOylation not only increases the affinity of Atx3 for p97, but also promotes a faster association. The mechanism by which SUMO conjugation to Atx3 might increase the affinity to p97 remains unclear. Even though SUMO1 does not directly interact in vitro with p97 ( Fig. S7) , analysis of the amino acid sequence of p97 reveals the presence of a putative SUMOinteracting motif (SIM) sequence, 429 LIDL 432 [63, 64] . Therefore, one possible explanation is that binding to Atx3 may provide an anchoring site and orient the SUMO protein for optimal interaction with p97 Table 2 ) using the global data analysis option available within BIAevaluation software. SIM, thereby facilitating the formation of a more stable complex. Alternatively, one cannot discard the existence of a second p97-binding site in Atx3 that becomes available upon covalent attachment of SUMO to the C-terminal region of Atx3. SUMOylation of Atx3 and a consequent modification of its affinity towards p97 are expected to have an impact on the biological function of both proteins. Both Atx3 and p97 share a role on protein degradation pathways [65] . While p97 is specifically involved in the extraction of polyubiquitinated proteins from the ER to the cytosol, Atx3 functions as an ubiquitin chain-editing enzyme [65] . Interestingly, Atx3 seems to decrease the interaction of p97 with ubiquitinated proteins by competing with Ufd1, a p97 molecular partner involved in ER-associated degradation (ERAD) [7] . This suggests that Atx3 might function as a modulator of ER-associated protein degradation by controlling p97-dependent protein extraction from the ER [7] . Considering that the affinity of p97 for the Ufd1/Npl4 heterodimer is in the low micromolar range (2.1 μM) [66] , thus approximately 1700-fold lower than the affinity for unmodified Atx3, and the high intracellular p97:Atx3 ratio, it is tempting to speculate that Atx3 might be playing a preponderant role on a large number of cellular processes mediated by p97. Atx3 SUMOylation may then act as a signal to trigger association with p97, adding a new level of regulation in the p97-mediated ERassociated protein degradation process. p97 was also shown to influence the aggregation of a polyQexpanded Atx3 fragment in vitro and to modulate neurodegeneration in a Drosophila melanogaster disease model [48] . Surprisingly, this effect was dependent on the concentration of p97, with low concentrations stimulating the self-assembly and neurotoxicity of the Atx3 fragment and high concentrations suppressing those effects. Given the influence of Atx3 SUMOylation on the affinity towards p97, it is tempting to speculate that this posttranslational modification might be contributing for a decrease in Atx3 self-assembly, either directly by reducing the JDmediated self-assembly step or indirectly, through the promotion of a faster and stronger association with p97, mimicking the Atx3 aggregation-suppression phenomenon observed for high concentrations of p97 [48] . The exact determination of the cellular conditions that favor Atx3 SUMOylation and binding to p97 is therefore relevant to elucidate the potential role of the interplay between this posttranslational modification and molecular interactions for MJD therapy.
Transparency document
The Transparency document associated with this article can be found, in the online version.
